Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Allakos Inc

ALLK
Current price
2.99 USD -0.02 USD (-0.66%)
Last closed 3 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 199 445 968 USD
Yield for 12 month -60.03 %
Week
Month
Year
ALLK
21.11.2021 - 28.11.2021

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California. Address: 975 Island Drive, Redwood City, CA, United States, 94065

Analytics

WallStreet Target Price

9.58 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures ALLK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -180 084 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -33.15 %
PEG Ratio
Return On Equity TTM -58.79 %
Wall Street Target Price 9.58 USD
Revenue TTM
Book Value 2.53 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -1.53 USD
Diluted Eps TTM -1.53 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ALLK

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALLK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALLK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.2789
Price Book MRQ 0.9043

Financials ALLK

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ALLK

For 52 weeks

1.48 USD 8.73 USD
50 Day MA 2.02 USD
Shares Short Prior Month 3 952 946
200 Day MA 3.85 USD
Short Ratio 5.6
Shares Short 3 433 604
Short Percent 5.15 %